EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Population snapshot of Streptococcus pneumoniae causing invasive disease among adults aged ≥18 years in South Africa before and after implementation of pneumococcal conjugate vaccines in 2005–2020

Kedibone Maria Ndlangisa, Cebile Lekhuleni, Happy Skosana, Linda de Gouveia, Susan Meiring, Sibongile Walaza, Vanessa Quan, Stephen D Bentley, Stephanie W Lo, Cheryl Cohen, Anne von Gottberg, Mignon du Plessis

Microbial Genomics · 19.11.2025 · 11 (11)

DOI: 10.1099/mgen.0.001559 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbial Genomics, erschienen am 19.11.2025. Verfasst von Kedibone Maria Ndlangisa und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Institute for Communicable Diseases (NICD), a Division of the National Health Laboratory Service, Johannesburg, South Africa. Hauptthemen laut MEDLINE: Streptococcus pneumoniae, Pneumococcal Infections, Pneumococcal Vaccines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FIC NIH HHS, Gates Foundation, U.S. President’s Emergency Plan for AIDS Relief.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Routine use of pneumococcal conjugate vaccines (PCV) in South Africa caused a decline in vaccine-associated invasive pneumococcal disease (IPD), followed by the emergence of non-PCV serotypes, driven mainly by pre-existing lineages. We determined the molecular epidemiology of isolates causing IPD among adults in South Africa from 2020 to 2025 before and following the implementation of PCV in 2009. We performed whole-genome sequencing on randomly selected isolates causing IPD among adults aged ≥18 years ( N =1 581) during the four vaccine periods [pre-PCV (2005–2008), PCV7 (2009–2010), early-PCV13 (2011–2014) and late-PCV13 (2015–2020)]. We assigned in silico serotype, multi-locus sequence type, clonal complex (CC) and global pneumococcal sequence cluster (GPSC) and determined antimicrobial non-susceptibility profiles in silico . Poisson regression was used to calculate incidence rate ratios of imputed individual GPSC lineages using IPD incidence rate estimated per year for the three vaccine periods (PCV7, early-PCV13 and late-PCV13), compared to the pre-PCV period. Overall, our dataset represented 3.7% ( n =270), 3.4% ( n =128), 4.9% ( n =287) and 13.5% ( n =896) of adult pneumococcal isolates received during the four periods, respectively. We identified 135 GPSCs with the majority of isolates [68.7%(1 086/1 581)] clustering into 1 of 23 dominant GPSCs defined as GPSCs that comprised ≥20 genomes in the dataset. Compared to the pre-PCV7 period, a decrease in incidence of vaccine type lineages normally associated with vaccine serotypes was observed during the late-PCV13 period. GPSC2 (serotype 1) declined from 1.4 to 0.039/100,000 population ( P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Streptococcus pneumoniaePneumococcal InfectionsPneumococcal VaccinesHumansSouth AfricaAdultWhole Genome SequencingMiddle AgedVaccines, ConjugateMaleSerogroupFemaleMultilocus Sequence TypingAdolescentYoung AdultAgedMolecular EpidemiologyGenome, Bacterial

Stichwörter der Autor:innen

global pneumococcal sequence cluster (GPSC)pneumococcal conjugate vaccine (PCV)pneumococcus

Substanzen

Pneumococcal VaccinesVaccines, Conjugate

Autor:innen und Institutionen

  • National Institute for Communicable Diseases (NICD), a Division of the National Health Laboratory Service, Johannesburg, South Africa.
  • School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
  • Pathogen and Microbes, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Milner Centre for Evolution, Department of Life Sciences, University of Bath, Bath, UK.
  • Division of Medical Microbiology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

Förderung

  • FIC NIH HHS
  • Gates Foundation
  • U.S. President’s Emergency Plan for AIDS Relief
  • Pfizer South Africa
  • Bill and Melinda Gates Foundation
  • Fogarty International Center Global Infectious Disease
  • Fleming fund

Zitieren

APA

Ndlangisa, K. M., Lekhuleni, C., Skosana, H., de Gouveia, L., Meiring, S., Walaza, S., Quan, V., Bentley, S. D., Lo, S. W., Cohen, C., von Gottberg, A., & du Plessis, M. (2025). Population snapshot of Streptococcus pneumoniae causing invasive disease among adults aged ≥18 years in South Africa before and after implementation of pneumococcal conjugate vaccines in 2005–2020. Microbial Genomics, 11(11). https://doi.org/10.1099/mgen.0.001559

Vancouver

Ndlangisa KM, Lekhuleni C, Skosana H, de Gouveia L, Meiring S, Walaza S, et al. Population snapshot of Streptococcus pneumoniae causing invasive disease among adults aged ≥18 years in South Africa before and after implementation of pneumococcal conjugate vaccines in 2005–2020. Microbial Genomics. 2025;11(11). doi:10.1099/mgen.0.001559

BibTeX
@article{Ndlangisa2025,
  author = {Ndlangisa, Kedibone Maria and Lekhuleni, Cebile and Skosana, Happy and de Gouveia, Linda and Meiring, Susan and Walaza, Sibongile and Quan, Vanessa and Bentley, Stephen D and Lo, Stephanie W and Cohen, Cheryl and von Gottberg, Anne and du Plessis, Mignon},
  title = {Population snapshot of Streptococcus pneumoniae causing invasive disease among adults aged ≥18 years in South Africa before and after implementation of pneumococcal conjugate vaccines in 2005–2020},
  journal = {Microbial Genomics},
  year = {2025},
  volume = {11},
  number = {11},
  doi = {10.1099/mgen.0.001559}
}
Kostenlos starten →